Angiology Topic Homepage

Learning Zones

,

The Anticoagulation Video Channel* is intended for primary care practitioners and specialists involved in the treatment and follow up care of patients with atrial fibrillation (AF) or venous thromboembolism (VTE). It provides an overview of how to prevent stroke and systemic embolism in nonvalvular AF patients and how to prevent and treat VTE.

Users can expect to find the following videos readily available on the video channel with regular updates:

  • The benefits of dabigatran in preventing stroke in atrial fibrillation patients
    (Hans-Christoph Diener, Gregory YH Lip and John Eikelboom)
  • Dabigatran for the treatment and prevention of DVT and PE
    (Samuel Z Goldhaber)
  • The safety profile of dabigatran
    (Hans-Christoph Diener, John Eikelboom and Jeffrey Weitz)

Healthcare professionals should return often to avoid missing out on new content.

*The Anticoagulation Video Channel has been supported by an educational grant from Boehringer Ingelheim, who provided the videos, and is intended for healthcare professionals outside the USA, Canada and UK.

,Thrombosis Educational Portal

The Thrombosis Educational Portal is intended for healthcare professionals involved in the treatment and management of venous and arterial thrombosis. This resource is organised around the following sections:

  • Thrombosis
  • VTE Prevention
  • VTE Treatment
  • Atrial Fibrillation
  • Acute Coronary Syndrome (ACS)

This resource is intended to provide information to an international audience outside of the UK and the USA.

Clinical Case Studies

Massive Pulmonary Embolism

Respiratory Medicine & Allergy: Pulmonary Vascular Diseases

Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK
Christopher Kosky, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK

Case History
A 46-year-old Afro-Caribbean man presented to hospital after he collapsed with brief loss of consciousness. He was short of breath at rest and felt as if he couldn't take a breath in.

Sickle Cell Lung Disease

Respiratory Medicine & Allergy: Pulmonary Vascular Diseases

Elizabeth Hadley, Consultant Respiratory and General Physician, Barking, Havering and Redbridge Hospitals University NHS Trust, London, UK
Boris Lams, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK
Christopher Kosky, Consultant Respiratory Physicians, Guy's and St Thomas' NHS Foundation Trust, London, UK

Case History
A 40-year-old man with known homozygous (HbSS) sickle cell disease (SCD) presented to the emergency department with a three-day history of cough, fever and sweats. He denied any chest pain.

Latest News

Medical Videos

A Guide to the Coronary Angioplasty Procedure
A Guide to the Coronary Angioplasty Procedure
Flash Lecture: Changes in Antithrombotic Use
Flash Lecture: Changes in Antithrombotic Use
Rivaroxaban vs enoxaparin for the Prevention of Venous Thromboembolism
Rivaroxaban vs enoxaparin for the Prevention of Venous Thromboembolism
Diabetic Peripheral Arterial Disease (P.A.D.)
Diabetic Peripheral Arterial Disease (P.A.D.)
Does chronic venous insufficiency play a role in MS pathogenesis? Commentary (CONy 2010)
Does chronic venous insufficiency play a role in MS pathogenesis? Commentary (CONy 2010)
Advances in Dual Antiplatelet Therapy for Acute Coronary Syndrome (ACS)
Advances in Dual Antiplatelet Therapy for Acute Coronary Syndrome (ACS)

Recent Drug Updates

Medical Journal Abstracts on Angiology

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy.

Tue 05 Apr 2016 -  Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy.

Background: Azilsartan (AZI) is a relatively new angiotensin receptor blocker available for the treatment of any stage of hypertension, which was eventually given in combination with chlorthalidone ...

Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines.

Fri 01 Apr 2016 -  Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines.

The effect and clinical benefit of P2Y12 receptor antagonists may not be limited to platelet inhibition and the prevention of arterial thrombus formation. Potential additional effects include ...

Medical Images

Chest radiograph of sickle cell lung disease
Chest radiograph of sickle cell lung disease
Pulmonary arteriovenous malformation
 Pulmonary arteriovenous malformation
Sickle cell lung disease
Sickle cell lung disease
Pulmonary angiogram
Pulmonary angiogram

Clinical Guidelines

2016 European Guidelines on cardiovascular disease prevention in clinical practice

May 2016

The present guidelines represent an evidence-based consensus of the 6th European Joint Task..

... Force  involving 10 professional societies.This document has been developed to support healthcare professionals communicating with individuals about their cardiovascular (CV) risk and the benefits of a healthy lifestyle and early modification of their CV risk. In addition, the guidelines provide tools for healthcare professionals to promote population-based strategies and integrate these into national or regional prevention frameworks and to translate these in locally delivered healthcare services, in line with the recommendations of the World Health Organization (WHO) global status report on non-communicable diseases 2010.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

May 2016

The aim of this document is to provide practical, evidence-based guidelines for the diagnosis and..

... treatment of HF. The principal changes from the 2012 guidelines relate to:

I. a new term for patients with HF and a left ventricular ejection fraction (LVEF) that ranges from 40 to 49% — ‘HF with mid-range EF (HFmrEF)’; we believe that identifying HFmrEF as a separate group will stimulate research into the underlying characteristics, pathophysiology and treatment of this population;
II. clear recommendations on the diagnostic criteria for HF with reduced EF (HFrEF), HFmrEF and HF with preserved EF (HFpEF);
III. a new algorithm for the diagnosis of HF in the non-acute setting based on the evaluation of HF probability;
IV. recommendations aimed at prevention or delay of the development of overt HF or the prevention of death before the onset of symptoms;
V. indications for the use of the new compound sacubitril/valsartan, the first in the class of angiotensin receptor neprilysin inhibitors (ARNIs);
VI. modified indications for cardiac resynchronization therapy (CRT);
VII. the concept of an early initiation of appropriate therapy going along with relevant investigations in acute HF that follows the ‘time to therapy’ approach already well established in acute coronary syndrome (ACS);
VIII. a new algorithm for a combined diagnosis and treatment approach of acute HF based on the presence/absence of congestion/hypoperfusion.

Clinical Trials

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (PIONEER 6)

-30 days ago

This trial is conducted globally. The aim of the trial is to investigate the cardiovascular safety of oral semaglutide in subjects with type 2 ...

FRactional Flow Reserve Versus Angiography-Guided Strategy for Management of Non-Infarction RElated Artery Stenosis in Patients With Acute ST-segment Elevation Myocardial Infarction (FRAME-STEMI)

today

The aim of the study is to compare clinical outcomes following fractional flow reserve (FFR)-guided versus angiography only guided strategy in treatment of non-infarction related artery (non-IRA) ...

Back to top